Osteoporosis Screening — USMLE Step 2 CK Guide 2026

About This Page

This is a clinician-written, evidence-based summary aligned to the USMLE Step 2 CK Content Outline. It is intended for medical students preparing for USMLE Step 2 CK. Management reflects current ACC/AHA, USPSTF, and APA guidelines. Always cross-reference with UpToDate, institutional protocols, and clinical judgment.

Key points

USPSTF: screen all women age >=65 for osteoporosis with bone measurement testing
Screen postmenopausal women younger than 65 if they have risk factors and increased fracture risk by clinical risk assessment
Evidence is insufficient for routine osteoporosis screening in men under USPSTF, but evaluate men with fragility fracture or major risk factors
DEXA T-score: normal >=-1.0, osteopenia -1.0 to -2.5, osteoporosis <=-2.5
Fragility hip or vertebral fracture generally warrants osteoporosis treatment regardless of DEXA result

Overview

Osteoporosis is reduced bone strength leading to increased fragility fracture risk. Screening aims to identify patients at high risk before hip, vertebral, and wrist fractures occur. The USPSTF recommends screening women age 65 years or older and postmenopausal women younger than 65 with increased risk. Step 2 CK commonly tests who should get DEXA, how to interpret T-scores, when to use FRAX, and when a fragility fracture itself establishes a treatment indication.

Epidemiology

Osteoporotic fractures cause substantial morbidity, mortality, loss of independence, and healthcare costs. Hip fractures in older adults are associated with high one-year mortality and institutionalization. Major risk factors include age, female sex, postmenopausal estrogen deficiency, low body weight, parental hip fracture, smoking, excess alcohol, glucocorticoid use, rheumatoid arthritis, prior fragility fracture, and secondary causes such as hyperthyroidism, hyperparathyroidism, malabsorption, CKD, and hypogonadism.

Screening Criteria and Risk Factors

Symptoms

Asymptomatic woman age >=65 presenting for preventive care: screen with DEXA

Postmenopausal woman <65 with low body weight, parental hip fracture, smoking, excess alcohol, or glucocorticoid use: assess fracture risk and screen if increased

Low-trauma fracture from standing height or less suggests fragility fracture and requires osteoporosis evaluation/treatment

Back pain with height loss or kyphosis may indicate vertebral compression fracture

Chronic prednisone use equivalent to >=5 mg/day for >=3 months is a major secondary osteoporosis risk factor

Signs

Loss of height, thoracic kyphosis, reduced mobility, poor balance, or prior wrist/hip fracture increases concern

Focal vertebral tenderness after minor trauma may indicate compression fracture

Low BMI is a fracture risk factor; obesity does not eliminate osteoporosis risk

Signs of secondary causes: thyroid disease, Cushing features, malabsorption, chronic liver disease, or hypogonadism

Screening Tests and Interpretation

First-line

Central DEXA scanPreferred screening test at femoral neck, total hip, and lumbar spine. T-score compares to young healthy adult reference population

T-score interpretationNormal >=-1.0; osteopenia -1.0 to -2.5; osteoporosis <=-2.5; severe osteoporosis = T-score <=-2.5 plus fragility fracture

FRAXEstimates 10-year probability of major osteoporotic and hip fracture using clinical risk factors with or without femoral neck BMD

Second-line

Secondary cause labsCalcium, creatinine, 25-OH vitamin D, TSH, PTH, CBC, CMP, phosphate, testosterone in selected men, celiac testing if malabsorption suspected

Vertebral imagingConsider if height loss, back pain, kyphosis, or DEXA suggests high risk for occult vertebral compression fracture

Fall risk assessmentGait, balance, vision, orthostatic hypotension, sedating medications, home hazards, and vitamin D deficiency contribute to fracture risk

Specialist

Endocrinology/rheumatology referralFor premenopausal osteoporosis, very low T-score, recurrent fractures, secondary causes, CKD-mineral bone disease, or failure of therapy

Bone turnover markersMay help selected specialists monitor adherence or response but are not routine Step 2 screening tests

Screening and Prevention Strategy

USPSTF Osteoporosis Screening Recommendation 2025; US osteoporosis treatment principles

Who to screen

Women age >=65: screen with DEXA
Postmenopausal women <65: screen if risk factors and increased fracture risk by clinical risk assessment
Men: USPSTF evidence insufficient for routine population screening, but evaluate if fragility fracture, hypogonadism, glucocorticoid use, or other major risk factor
Do not use serum calcium or vitamin D as the primary screening test for osteoporosis

General prevention

Weight-bearing and resistance exercise
Fall prevention: vision correction, home safety, balance training, medication review, and assistive devices when needed
Adequate calcium intake from diet/supplements and vitamin D repletion when deficient
Smoking cessation and limiting alcohol

When to treat

Hip or vertebral fragility fracture: treat regardless of T-score
T-score <=-2.5 at hip, femoral neck, or spine: treat
Osteopenia plus high FRAX risk: treatment is often indicated using US thresholds such as hip fracture risk >=3% or major osteoporotic fracture risk >=20%
Bisphosphonates are first-line for many patients: alendronate, risedronate, zoledronic acid

Medication considerations

Oral bisphosphonates: take with water on empty stomach and remain upright for at least 30 minutes
Avoid oral bisphosphonates in esophageal disorders or inability to sit upright; use caution in severe renal impairment
Denosumab is an alternative but discontinuation can cause rebound vertebral fractures unless transitioned
Anabolic therapy may be used for very high fracture risk under specialist care

Complications

Hip fracture: High mortality, loss of independence, delirium, venous thromboembolism, and institutionalization
Vertebral compression fracture: Back pain, kyphosis, height loss, restrictive lung mechanics, and chronic pain
Wrist fracture: Often early fragility fracture signal
Bisphosphonate adverse effects: Esophagitis, musculoskeletal pain, rare osteonecrosis of jaw, rare atypical femoral fracture
Undiagnosed secondary disease: Hyperparathyroidism, myeloma, malabsorption, or endocrine disease can be missed if risk pattern is atypical

USMLE Step 2 CK Exam Tips

1Woman age 65+ = DEXA screening, even if asymptomatic
2T-score <=-2.5 = osteoporosis; -1.0 to -2.5 = osteopenia
3Fragility hip or vertebral fracture = treat osteoporosis regardless of DEXA
4FRAX helps decide treatment in osteopenia and screening in younger postmenopausal women
5Men are not routine USPSTF screening candidates, but a man with fragility fracture or chronic steroids needs evaluation
6Oral bisphosphonate counseling: empty stomach, water, stay upright
7Chronic glucocorticoids are a major osteoporosis risk factor
8Do not order DEXA for every premenopausal woman; look for secondary causes or fragility fracture

Put your reading into practice

Topic-specific question practice is not linked for this article yet.

Choose USMLE Step 2 CK questions from the existing bank. General exam practice covers your selected topics; it is not filtered to this article. Your usual question-bank access applies.

Choose USMLE Step 2 CK practice

After your session, return to this section to revisit the reading and choose your next review.

regional clinical guidance